
Arbutus Biopharma Corporation: updates and filings
Price
$4.02
November 20, 2026Market cap $799M
What Ploutos Investor adds for Arbutus Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
July 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 12, 2026Other material eventsForm8-K
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 22, 2026Other material eventsForm8-K
- Oct 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 5, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 1, 2026Filing (amendment)FormSC TO-I/A
- Sep 30, 2026Filing (amendment)FormSC TO-I/A
- Sep 4, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 24, 2026FilingFormSC TO-I
- Aug 21, 2026FilingFormSC TO-C
- Aug 21, 2026Other material eventsForm8-K
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 16, 2026Material agreement ended, officer or director change, other material eventsForm8-K
- Jun 5, 2026Shares registered for employeesFormS-8
- May 27, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 12, 2026 | 8-K | Other material events | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 22, 2026 | 8-K | Other material events | Document |
| Oct 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 5, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 1, 2026 | SC TO-I/A | Filing (amendment) | Document |
| Sep 30, 2026 | SC TO-I/A | Filing (amendment) | Document |
| Sep 4, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 24, 2026 | SC TO-I | Filing | Document |
| Aug 21, 2026 | SC TO-C | Filing | Document |
| Aug 21, 2026 | 8-K | Other material events | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 16, 2026 | 8-K | Material agreement ended, officer or director change, other material events | Document |
| Jun 5, 2026 | S-8 | Shares registered for employees | Document |
| May 27, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 30, 2008.
The full analysis
What do Arbutus Biopharma's filings show?
The filings are where every one of Arbutus Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.